Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 6262-year-old man is hospitalized for the management of a right lower extremity deep vein thrombosis and a pulmonary embolism. He was admitted 55 days ago and immediately started on a continuous intravenous unfractionated heparin infusion. His symptoms of dyspnea and leg swelling have significantly improved. He has no active bleeding, and physical examination is unremarkable except for mild residual edema in the right calf. Today, his vital signs are stable.

Serial laboratory results are as follows:

ParameterDay 1 (Admission)Day 5 (Today)
Hemoglobin14.2 g/dL14.2 \text{ g/dL}13.9 g/dL13.9 \text{ g/dL}
Platelet count240,000/mm3240,000/\text{mm}^3110,000/mm3110,000/\text{mm}^3
Serum creatinine1.1 mg/dL1.1 \text{ mg/dL}1.1 mg/dL1.1 \text{ mg/dL}

Which of the following is the best next step in the management of this patient?

  1. A
    Discontinue unfractionated heparin and begin enoxaparin
  2. B
    Continue unfractionated heparin and order a serotonin release assay
  3. Discontinue unfractionated heparin and begin argatrobanCevap
  4. D
    Continue unfractionated heparin and transfuse pooled platelets
  5. E
    Discontinue unfractionated heparin and begin warfarin

Cevap

Discontinue unfractionated heparin and begin argatroban
This patient has developed a >50%>50\% drop in platelets 55 days after the initiation of unfractionated heparin, which is the classic presentation of Type 2 heparin-induced thrombocytopenia (HIT). HIT is a life-threatening, immune-mediated prothrombotic disorder caused by antibodies against heparin-platelet factor 4 (PF4) complexes. The most critical step in monitoring and treatment evaluation when HIT is suspected is the immediate discontinuation of all heparin products (including flushes) and the prompt initiation of a direct thrombin inhibitor (such as argatroban or bivalirudin) or a factor Xa inhibitor (like fondaparinux). This prevents further consumptive coagulopathy and catastrophic thrombotic events such as stroke, myocardial infarction, or limb ischemia.

Adım Adım Çözüm

1
Evaluate the patient's laboratory trends during treatment.
The platelet count dropped from 240,000/mm3240,000/\text{mm}^3 to 110,000/mm3110,000/\text{mm}^3 (a >50%>50\% decrease) precisely 55 days after starting unfractionated heparin.
Monitoring platelet counts is essential in patients receiving heparin to detect early signs of heparin-induced thrombocytopenia (HIT).
2
Calculate the pretest probability of HIT using the 4Ts score.
The patient scores points for a >50%>50\% platelet fall (2 points) and typical timing of 55 to 1010 days (2 points), indicating a moderate-to-high probability of HIT.
A moderate-to-high pretest probability mandates immediate changes in the treatment plan.
3
Determine the best next step in management based on the suspected diagnosis.
All heparin products must be discontinued, and an alternative, non-heparin anticoagulant (such as argatroban) must be initiated immediately.
Continuing heparin or delaying treatment while awaiting confirmatory testing (like a serotonin release assay) puts the patient at extreme risk for new arterial or venous thromboses.

Anahtar Kavram

Monitoring for Heparin-Induced Thrombocytopenia (HIT) and subsequent treatment adaptation
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru